These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36442773)

  • 1. Luteolin inhibits the TGF-β signaling pathway to overcome bortezomib resistance in multiple myeloma.
    Li Z; Wang H; Wang Y; Ma Z; Hu L; Luo S; Gong Y; Zhu L; Gong H; Xiang R; Zhu Y; Xie Y; Yang C; Peng H; Liu J; Xiao X
    Cancer Lett; 2023 Feb; 554():216019. PubMed ID: 36442773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lycorine targets multiple myeloma stem cell-like cells by inhibition of Wnt/β-catenin pathway.
    Wang H; Gong Y; Liang L; Xiao L; Yi H; Ye M; Roy M; Xia J; Zhou W; Yang C; Shen X; Zhang B; Li Z; Liu J; Zhou H; Xiao X
    Br J Haematol; 2020 Jun; 189(6):1151-1164. PubMed ID: 32167591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Albendazole inhibits NF-κB signaling pathway to overcome tumor stemness and bortezomib resistance in multiple myeloma.
    Yi H; Liang L; Wang H; Luo S; Hu L; Wang Y; Shen X; Xiao L; Zhang Y; Peng H; Dai C; Yuan L; Li R; Gong F; Li Z; Ye M; Liu J; Zhou H; Zhang J; Xiao X
    Cancer Lett; 2021 Nov; 520():307-320. PubMed ID: 34390764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma.
    Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K
    J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma.
    Lee SW; Yeon SK; Kim GW; Lee DH; Jeon YH; Yoo J; Kim SY; Kwon SH
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma.
    Dutta D; Liu J; Wen K; Kurata K; Fulciniti M; Gulla A; Hideshima T; Anderson KC
    Blood Cancer J; 2023 Dec; 13(1):184. PubMed ID: 38072962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polyphyllin VII, a novel moesin inhibitor, suppresses cell growth and overcomes bortezomib resistance in multiple myeloma.
    Wang H; Xiao X; Li Z; Luo S; Hu L; Yi H; Xiang R; Zhu Y; Wang Y; Zhu L; Xiao L; Dai C; Aziz A; Yuan L; Cui Y; Li R; Gong F; Liu X; Liang L; Peng H; Zhou H; Liu J
    Cancer Lett; 2022 Jul; 537():215647. PubMed ID: 35306105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Research Progress on Mechanism of Bortezomib Resistance in Multiple Myeloma].
    Wang YR; Ma YP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1584-1587. PubMed ID: 37846721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone-Targeted Bortezomib Inhibits Bortezomib-Resistant Multiple Myeloma in Mice by Providing Higher Levels of Bortezomib in Bone.
    Tao J; Srinivasan V; Yi X; Zhao Y; Zhang H; Lin X; Zhou X; Boyce BF; Villalta PW; Ebetino FH; Ho KK; Boeckman RK; Xing L
    J Bone Miner Res; 2022 Apr; 37(4):629-642. PubMed ID: 34970782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-Aza-2'-Deoxycytidine Alters the Methylation Profile of Bortezomib-Resistant U266 Multiple Myeloma Cells and Affects Their Proliferative Potential.
    Łuczkowska K; Kulig P; Rusińska K; Baumert B; Machaliński B
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining luteolin and curcumin synergistically suppresses triple-negative breast cancer by regulating IFN and TGF-β signaling pathways.
    Wang X; Zhang L; Si H
    Biomed Pharmacother; 2024 Sep; 178():117221. PubMed ID: 39111078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe.
    Hu L; Li B; Chen G; Song D; Xu Z; Gao L; Xi M; Zhou J; Li L; Zhang H; Feng Q; Wang Y; Lu K; Lu Y; Bu W; Wang H; Wu X; Zhu W; Shi J
    J Exp Clin Cancer Res; 2020 Jun; 39(1):105. PubMed ID: 32517809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Evidence That 25(OH)D3 and VK2 MK-7 Vitamins Influence the Proliferative Potential and Gene Expression Profiles of Multiple Myeloma Cells and the Development of Resistance to Bortezomib.
    Łuczkowska K; Kulig P; Baumert B; Machaliński B
    Nutrients; 2022 Dec; 14(23):. PubMed ID: 36501221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Wee1 kinase inhibitor MK1775 suppresses cell growth, attenuates stemness and synergises with bortezomib in multiple myeloma.
    Liang L; He Y; Wang H; Zhou H; Xiao L; Ye M; Kuang Y; Luo S; Zuo Y; Feng P; Yang C; Cao W; Liu T; Roy M; Xiao X; Liu J
    Br J Haematol; 2020 Oct; 191(1):62-76. PubMed ID: 32314355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10.
    Xi H; Li L; Du J; An R; Fan R; Lu J; Wu YX; Wu SX; Hou J; Zhao LM
    Oncol Rep; 2017 Feb; 37(2):961-968. PubMed ID: 28000886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solamargine induces autophagy-mediated apoptosis and enhances bortezomib activity in multiple myeloma.
    Han Q; Bai H; Xu Y; Zhou M; Zhou H; Dong X; Chen B
    Clin Exp Pharmacol Physiol; 2022 Jun; 49(6):674-685. PubMed ID: 35294057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STMN1 promotes cell malignancy and bortezomib resistance of multiple myeloma cell lines via PI3K/AKT signaling.
    Wang L; Cao J; Tao J; Liang Y
    Expert Opin Drug Saf; 2024 Mar; 23(3):277-286. PubMed ID: 37642368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel alkaloid compound, DCZ0358, exerts significant antitumor activity in bortezomib-resistant multiple myeloma cells through inhibition of JAK2/STAT3 pathway.
    Zhang B; Li B; Xie Y; Chang S; Xu Z; Hu H; Chen G; Zhang T; He J; Wu X; Zhu H; Lai W; Song D; Lu Y; Jia X; Zhu W; Shi J
    Acta Biochim Biophys Sin (Shanghai); 2023 Feb; 55(2):215-224. PubMed ID: 36815376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy.
    Zhang M; He J; Liu Z; Lu Y; Zheng Y; Li H; Xu J; Liu H; Qian J; Orlowski RZ; Kwak LW; Yi Q; Yang J
    Oncotarget; 2015 Apr; 6(11):8567-78. PubMed ID: 25895124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulation.
    Jin S; Li B; Zhang B; Gao X; Jia X; Xu L; Chang S; Hu K; Wang G; Xu Z; Zhang T; Song D; Yang G; Wu X; Zhu H; Huang C; Lu Y; Shi J; Zhu W; Chen G
    Acta Biochim Biophys Sin (Shanghai); 2023 Dec; 55(12):1884-1891. PubMed ID: 38009004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.